Tolnaftate, the active ingredient of Tolnaftate-D, is already approved as a treatment of jock itch, athlete’s foot and ringworm.
Apricus Biosciences wholly owned subsidiary NexMed’s Tolnaftate-D uses NexACT technology, the company’s proprietary drug delivery technology, which transiently loosens the tight junction between the cells of the sealed skin to allow more permeation.
Apricus Bio president, chairman and CEO Bassam Damaj said being added to the monograph permits them to work with other companies in developing combinations of their NexACT technology with the potentially hundreds of active ingredients listed in the monograph and to develop their proprietary drugs using NexACT at the concentration used in our approved Tolnaftate-D OTC drug.